Preclinical News and Research

RSS
TPP raises £9.6M to develop early-stage pre-clinical drug candidates

TPP raises £9.6M to develop early-stage pre-clinical drug candidates

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco Technologies third-quarter net loss increases to $5.28M

Senesco Technologies third-quarter net loss increases to $5.28M

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes

Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes

Pfizer, Washington University announce indications discovery collaboration

Pfizer, Washington University announce indications discovery collaboration

MorphoSys AG (DE) - AbD Serotec enters new growth area

MorphoSys AG (DE) - AbD Serotec enters new growth area

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies first-quarter net loss increases to $18.5 million

Soligenix first-quarter revenues decrease to $336,000

Soligenix first-quarter revenues decrease to $336,000

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

Athersys presents data supporting MultiStem programs

Athersys presents data supporting MultiStem programs

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

SANUWAVE Health reports $3.0 million net loss for first-quarter 2010

Poorly designed clinical trials adversely affect medical advances

Poorly designed clinical trials adversely affect medical advances

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.